Table 2.

Nurr1 ligand-mediated transcriptional changes.

Ligand	Target Genes	In Vitro/In Vivo Models	Ref.
Imidazopyridines	↑TH	Rat mesencephalic dopaminergic neurons	32
Imidazopyridines	↓IL-6	Poly(I:C)-lesioned mouse model of PD	32
AQ	↓IL-1β, ↓IL-6, ↓TNF-α, ↓iNOS	LPS-treated rat mesencephalic dopaminergic neurons	33
CQ	↑Nurr1, ↑Foxp3, ↑IL-2, ↑CD25, ↑FASL	Mouse primary naïve CD4+CD25−CD62Lhigh T cells	34
DHI	↑TH, ↑DAT, ↑VMAT2	Zebrafish	9
PGE1	↑TH, ↑DAT, ↑AADC, ↑VMAT2, ↑Pitx3, ↑c-Ret	MPP+-treated MN9D cells	10
PGE1	↑TH, ↑DAT, ↑AADC, ↑VMAT2	In vivo; midbrain	10
PGA1	↑TH, ↑DAT, ↑AADC, ↑VMAT2, ↑Pitx3, ↑c-Ret	MPP+-treated MN9D cells	10
PGA1	↑TH, ↑DAT, ↑AADC, ↑VMAT2	In vivo; midbrain	10

TH tyrosine hydroxylase, IL-6 Interleukin-6, IL-1β Interleukin-1β, TNF-α tumor necrosis factor-α, iNOS INDUCIBLE nitric oxide synthase, Nurr1 nuclear receptor related 1, Foxp3 forkhead box P3, IL-2 Interleukin-2, CD25 Interleukin-2 receptor alpha, VMAT2 vesicular monoamine transporter 2, DAT dopamine transporter, AADC aromatic l-amino acid decarboxylase, VMAT2 vesicular monoamine transporter 2, Pitx3 pituitary homeobox 3, c-Ret RET proto-oncogene